Search
for

    Learn

    5 / 10 results

      learn Dutasteride

      Heavy duty finasteride that comes with higher risks, but scalp injections seem safe and are gaining popularity

      learn Cyproterone

      a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor

      learn GT20029

      research compound made to degrade androgen receptors in scalp

      learn Rosemary

      herb and oil with stimulant, circulatory, anti-inflammatory and antioxidant properties

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community Bloodwork post finasteride gyno sides

      in Finasteride/Dutasteride  8 upvotes 3 years ago
      The user stopped using finasteride after two weeks due to gynecomastia symptoms and shared blood work results questioning if they indicate a cause for the side effects. The user is considering restarting finasteride and seeking advice on their blood work levels in relation to gynecomastia.

      community Trestolone (MENT) as a nuclear treatment

      in Treatment  99 upvotes 2 years ago
      Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

      community Is it possible that dutasteride won’t make you depressedd if finasteride did?

      in Chat  16 upvotes 6 months ago
      The conversation discusses whether dutasteride might cause less depression than finasteride for hair loss treatment, with some users suggesting it could due to different mechanisms of action or molecular size, while others express skepticism or share personal experiences with these medications.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  136 upvotes 6 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.